Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 24, 2026
DataAggregated Company Financials
Companies66
  • 7D-0.9%
  • 3M4.6%
  • 1Y7.9%
  • YTD-15.0%

Over the last 7 days, the Life Sciences industry has remained flat. The past year has been better, since the industry has gained 7.9% in that time. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Jun 2026US$574.0bUS$151.2bUS$13.7b40.6x41.9x3.8x
Fri, 22 May 2026US$541.7bUS$150.3bUS$14.0b33.4x38.7x3.6x
Sun, 19 Apr 2026US$595.2bUS$147.9bUS$14.1b38.3x42.3x4x
Tue, 17 Mar 2026US$536.3bUS$147.8bUS$14.0b34.3x38.3x3.6x
Thu, 12 Feb 2026US$609.3bUS$147.6bUS$12.9b32.9x47.3x4.1x
Sat, 10 Jan 2026US$691.5bUS$145.8bUS$12.4b37.1x55.9x4.7x
Mon, 08 Dec 2025US$662.3bUS$145.8bUS$12.5b35.7x53.1x4.5x
Wed, 05 Nov 2025US$643.0bUS$145.5bUS$12.1b33.9x53.3x4.4x
Fri, 03 Oct 2025US$623.9bUS$144.3bUS$14.6b32.2x42.9x4.3x
Sun, 31 Aug 2025US$585.1bUS$144.3bUS$14.6b29.2x40.2x4.1x
Tue, 29 Jul 2025US$585.5bUS$143.7bUS$8.8b37.9x66.5x4.1x
Thu, 26 Jun 2025US$527.7bUS$142.9bUS$9.2b36.1x57.5x3.7x
Sat, 24 May 2025US$500.2bUS$142.8bUS$9.1b31.6x55x3.5x
Mon, 21 Apr 2025US$503.7bUS$142.6bUS$10.0b34.3x50.6x3.5x
Wed, 19 Mar 2025US$600.9bUS$143.0bUS$9.8b39x61.2x4.2x
Fri, 14 Feb 2025US$628.2bUS$143.3bUS$11.0b35.3x57.1x4.4x
Sun, 12 Jan 2025US$671.3bUS$142.4bUS$10.2b43.2x65.8x4.7x
Tue, 10 Dec 2024US$664.3bUS$142.4bUS$10.2b44.8x65x4.7x
Thu, 07 Nov 2024US$700.3bUS$142.4bUS$10.4b43.4x67.4x4.9x
Sat, 05 Oct 2024US$732.4bUS$141.8bUS$8.5b37.6x86.2x5.2x
Mon, 02 Sep 2024US$749.5bUS$141.8bUS$8.5b37.8x88.2x5.3x
Wed, 31 Jul 2024US$732.5bUS$141.0bUS$12.6b37.7x58.3x5.2x
Fri, 28 Jun 2024US$685.8bUS$141.3bUS$12.2b37.9x56.3x4.9x
Sun, 26 May 2024US$726.8bUS$141.5bUS$12.4b38.7x58.5x5.1x
Tue, 23 Apr 2024US$682.2bUS$142.0bUS$12.8b40.8x53.3x4.8x
Thu, 21 Mar 2024US$746.6bUS$142.1bUS$12.8b44.3x58.2x5.3x
Sat, 17 Feb 2024US$720.5bUS$142.2bUS$12.5b43.3x57.5x5.1x
Mon, 15 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Wed, 13 Dec 2023US$653.3bUS$153.7bUS$14.2b35.6x45.9x4.2x
Fri, 10 Nov 2023US$592.6bUS$153.8bUS$10.9b30.3x54.3x3.9x
Sun, 08 Oct 2023US$644.8bUS$154.6bUS$11.2b33.1x57.6x4.2x
Tue, 05 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Thu, 03 Aug 2023US$731.4bUS$154.6bUS$11.5b31.8x63.5x4.7x
Sat, 01 Jul 2023US$697.8bUS$152.4bUS$12.5b29.5x55.8x4.6x
Price to Earnings Ratio

55.8x


Total Market Cap: US$697.8bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.9x which is lower than its 3-year average PE of 56.2x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.31%
Healthcare0.44%
Life Sciences-0.91%
Clinical Research and Equipment-0.91%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
WST West Pharmaceutical ServicesUS$336.392.1%
+US$481.1m		51.1%PE43.8x
MEDP Medpace HoldingsUS$473.482.6%
+US$339.3m		50.2%PE29.4x
ALMR Alamar BiosciencesUS$22.9414.4%
+US$199.6m		n/aPS18.2x
ABCL AbCellera BiologicsUS$5.6310.6%
+US$164.9m		53.0%PS21.7x
MTD Mettler-Toledo InternationalUS$1.16k0.4%
+US$102.5m		-2.4%PE26.7x

Latest News

TEM
US$48.61
Tempus AI
7D
-3.9%
1Y
-28.8%
A
US$126.67
Agilent Technologies
7D
-1.3%
1Y
7.7%
ILMN
US$164.93
Illumina
7D
0.4%
1Y
80.2%
DHR
US$178.97
Danaher
7D
-1.3%
1Y
-9.4%
WST
US$336.39
West Pharmaceutical Services
7D
2.1%
1Y
51.1%
Narrative Update • Jun 22

WST: Injectable Exposure And High Value Mix Will Shape Balanced Future Returns

Analysts have lifted their implied price target for West Pharmaceutical Services by about $6 to reflect updated fair value assumptions and ongoing confidence in injectable exposure, high value product momentum, and management execution highlighted in recent research. Analyst Commentary Recent research on West Pharmaceutical Services centers on how well the company is positioned in injectable markets and high value product categories, and how that ties into fair value and execution risk.
CRL
US$186.60
Charles River Laboratories International
7D
1.0%
1Y
25.7%
Analysis Article • Jun 21

Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade

Charles River Laboratories International stock reacts to new AI drug discovery collaboration Charles River Laboratories International (CRL) is back in focus after a Morgan Stanley upgrade and a new collaboration with Eli Lilly's AI and machine learning drug discovery platform, TuneLab. See our latest analysis for Charles River Laboratories International. The recent Morgan Stanley upgrade and the Lilly TuneLab collaboration arrive as momentum in Charles River Laboratories International’s share...
ABCL
US$5.63
AbCellera Biologics
7D
10.6%
1Y
53.0%
MTD
US$1,156.64
Mettler-Toledo International
7D
0.4%
1Y
-2.4%
Analysis Article • Jun 20

Mettler Toledo International (MTD) Stock Could Be 13.8% Undervalued After Earnings Beat

Fresh quarterly results and ownership trends have pushed Mettler-Toledo International (MTD) into focus after the company reported earnings that beat market expectations and year-over-year growth in both revenue and net profit. See our latest analysis for Mettler-Toledo International. Despite the upbeat earnings surprise and higher institutional ownership, Mettler-Toledo International’s 1-month share price return of 4.99% comes after the stock fell 18.89% year to date and its 1-year total...
VRXA
US$4.48
Veraxa Biotech
7D
-78.9%
1Y
-56.8%
WAT
US$357.20
Waters
7D
-0.9%
1Y
3.0%
Narrative Update • Jun 18

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).
BIO
US$270.32
Bio-Rad Laboratories
7D
-6.8%
1Y
13.6%
Narrative Update • Jun 18

BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price

Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.
MEDP
US$473.48
Medpace Holdings
7D
2.6%
1Y
50.2%
TMO
US$469.35
Thermo Fisher Scientific
7D
-0.7%
1Y
16.1%
Analysis Article • Jun 17

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...
STVN
US$16.87
Stevanato Group
7D
2.2%
1Y
-31.4%
Narrative Update • Jun 15

STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power

Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.
IQV
US$171.28
IQVIA Holdings
7D
-4.4%
1Y
8.0%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
ALMR
US$22.94
Alamar Biosciences
7D
14.4%
1Y
n/a